Summary of the Net Purchase Price and Allocation to the Acquired Assets (Detail) - ProstaGene, LLC	12 Months Ended
	May 31, 2019 USD ($)
Business Acquisition, Contingent Consideration [Line Items]
CytoDyn Inc. Equity	$ 11,558,000
Acquisition Expenses	741,297
Release of Deferred Tax Asset	2,826,919
Total Cost of Acquisition	15,126,216
Intangible assets	15,126,216
Other	0
Allocation of Acquisition Costs	$ 15,126,216